Mode
Text Size
Log in / Sign up

Long-term exercise significantly attenuates cardiac troponin I elevation in anthracycline-treated breast cancer patientsLong-term Exercise May Protect Heart Health After Breast Cancer Treatment

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that long-term exercise significantly reduces troponin I in anthracycline-treated patients, but cardioprotection is uncertain.

This meta-analysis evaluated the effects of long-term exercise (at least 12 weeks, at least 1 session per week) compared to usual care in breast cancer patients treated with anthracyclines. The study included a sample size of 360 patients to assess various markers of cardiac dysfunction.

The primary finding was a significant attenuation of cardiac troponin I elevation (SMD = -0.50; 95% CI, -0.93 to -0.06; p = 0.02). However, no statistically significant differences were observed between groups for secondary outcomes, including left ventricular ejection fraction, global longitudinal strain, cardiac troponin T, and N-terminal prohormone of brain natriuretic peptide.

Authors noted several limitations, including heterogeneous cancer populations in existing reviews, the need for larger and standardized trials, the requirement for advanced assessment modalities, and the need for longer follow-up periods. While the reduction in troponin I suggests a potential protective signal, the cardioprotective role of exercise remains uncertain. Clinical application is currently limited by these uncertainties and the need for more robust data.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the management of cancer therapy-related cardiac dysfunction in breast cancer patients. While previous coverage has focused on risk stratification tools like D-dimeromics and managing specific toxicities like hepatotoxicity from CDK4/6 inhibitors or skin toxicity from trolamine, this finding specifically addresses the impact of exercise on cardiac markers following anthracycline treatment.

A review of existing research looked at how regular exercise affects heart health in breast cancer patients who received anthracycline treatments. These specific medications are known to sometimes cause heart issues. The study looked at 360 patients to see if at least 12 weeks of weekly exercise could make a difference.

The analysis found that long-term exercise significantly reduced levels of cardiac troponin I. This specific marker is often used to identify heart muscle stress or damage. However, other measurements of heart function, such as ejection fraction and strain, did not show significant changes between the exercise group and the standard care group.

Because this was a review of different studies, the results are not definitive. The researchers noted that the groups were diverse and more large, standardized trials are needed to confirm these findings. While the reduction in troponin I is a positive signal, the exact role of exercise in protecting the heart remains uncertain. Patients should talk to their doctors about how exercise fits into their specific recovery plan.

What this means for you:
Exercise may lower a marker of heart stress in some breast cancer patients, but more research is needed.

Common questions

Can exercise help my heart after chemotherapy?

The study found that at least 12 weeks of weekly exercise significantly lowered cardiac troponin I, which is a marker of heart stress. However, other heart measurements did not show significant changes. Because the results are from a meta-analysis of various groups, you should talk to your doctor about the best exercise plan for your specific heart health.

What specific heart markers were affected by exercise?

The study specifically found a significant decrease in cardiac troponin I levels in patients who exercised for at least 12 weeks. Other markers, including cardiac troponin T and N-terminal prohormone of brain natriuretic peptide, did not show statistically significant differences between those who exercised and those who received standard care.

Is it safe to start an exercise program after treatment?

The study did not report any specific safety concerns or adverse events for the exercise group. However, the researchers noted that the cardioprotective role of exercise is still uncertain and more large, standardized trials are needed to confirm the findings. Always consult your medical team before starting a new exercise routine.

Study Details

Study typeMeta analysis
Sample sizen = 360
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
PURPOSE: Cancer therapy-related cardiac dysfunction (CTRCD) is a significant concern for breast cancer patients undergoing anthracycline-based chemotherapy. Although exercise has been proposed as a cardioprotective strategy, existing reviews have largely examined heterogeneous cancer populations receiving varied treatments, leaving a gap in the evidence base focused exclusively on anthracycline-induced CTRCD. This systematic review and meta-analysis aimed to address that gap by evaluating the effects of long-term exercise on key CTRCD markers in breast cancer patients treated exclusively with anthracyclines. METHODS: A comprehensive search of PubMed, Scopus, Cochrane Central Register of Controlled Trials, and Web of Science was conducted for randomized controlled trials including breast cancer patients undergoing anthracycline-based chemotherapy, receiving long-term exercise interventions (≥ 12 weeks, ≥ 1 session/week) compared to usual cancer care, and reporting at least one of the following outcomes: left ventricular ejection fraction, global longitudinal strain, cardiac troponin I, cardiac troponin T, or N-terminal prohormone of brain natriuretic peptide. RESULTS: Six randomized controlled trials involving 360 participants were included. Exercise significantly attenuated cardiac troponin I elevation compared to controls (SMD = -0.50; 95% CI, -0.93 to -0.06; p = 0.02). No statistically significant between-group differences were observed for left ventricular ejection fraction, global longitudinal strain, cardiac troponin T, or N-terminal prohormone of brain natriuretic peptide. CONCLUSION: The cardioprotective role of exercise during anthracycline treatment remains uncertain, though the attenuation of cardiac troponin I elevation suggests a potential protective signal warranting further investigation through larger, standardized trials employing advanced assessment modalities and longer follow-up periods.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.